Introduction
Atherosclerosis is increasingly considered as a low grade inflammatory response of the arterial wall to a variety of stimuli [Fuster&Lewis, 1994; Libby, 2001] . It is accepted that the adhesion of circulating leukocytes and monocytes to endothelial cells (EC) and subsequent transendothelial migration are an important step in the initiation and the development of atherosclerotic lesions [Hillis&Flapan, 1998; Jang, 1994] . This process is mediated by receptors expressed on the surface of vascular EC -cell adhesion molecules (CAM) under the action of an enhanced oxidative stress, lipopolysaccharide and proinflammatory cytokines. Vascular cell adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1) are two members of the immunoglobulin gene superfamily that play important but different roles in the adhesion of blood cells to the vascular endothelium. The significance of these molecules in the course of atherogenesis is confirmed by their immunohistochemically established elevated expression in the atherosclerotic plaques [Cybulsky&Gimbronejr, 1991; O'Brien et al., 1993] and by experimental models proving a delayed lesion development in case of their absence [Cybulsky et al., 2001] . Circulating forms of adhesion molecules that have been described are probably generated by cleavage to a site close to membrane insertion. The amount of ICAM-1 released has been demonstrated to be directly correlated with the surface expression of ICAM-1 in EC in culture and a correlation between plasma VCAM-1 and VCAM-1 mRNA has been reported in human atherosclerotic aorta [Leuwenberg et al., 1992; Pigott et al., 1992] . Levels of soluble cell adhesion molecules have been postulated to be useful risk predictor of cardiovascular events in healthy populations and various settings of ischemic heart disease [de Lemos et al., 2000; Hwang et al., 1997; Mulvihill et al., 2000 Mulvihill et al., , 2001 O'Malley et al., 2001; Ridker et al., 1998 ]. Nonetheless, the pathologic role of different soluble adhesion molecules in various stages of coronary artery disease is not fully defined. Two electrocardiographic markers -ventricular arrhythmias (VA), [Bigger et al., 1981; Farrell et al., 1991; Kostis et al., 1987] and impaired cardiac autonomic function, as indicated by depressed heart rate variability (HRV), [Bigger at al., 1992; Farrell et all, 1991; Hartikainen et al., 1996; Kleiger et al., 1987; Lanza et al., 1998 La Rovere et al., 1998 ] have been shown to predict mortality among patients recovering from acute myocardial infarction (MI). However there are only limited data about the prognostic value of depressed HRV in the whole spectrum of patients with ACS and few attempts to quantify the exact value of soluble adhesion molecules and HRV in the cumulative risk assessment of patients with ACS [Kennon et al., 2008; . Previous studies have shown that statin treatment improve the prognosis in patients with acute coronary syndromes [Kinlay et al., 2003; Ridker at al., 2005] . The reduction of clinical events secondary to lipid lowering has traditionally been attributed to reduction of cholesterol deposition and facilitation of cholesterol efflux from coronary plaques. However, several studies have recently suggested that the beneficial effects of statins in atherosclerotic disease may not be limited to the lipid-lowering effects of these drugs. Possible explanations for the observed reduction of morbidity and mortality with statin use include improvement of endothelial function, plaque stabilisation, and inhibition of the inflammatory response associated with atherosclerosis [Liao 2003; Ray&Cannon, 2005] . In the last years an antiarrhythmic effect of statins has been suggested and reported as a possible contributing mechanism. The aim of this study was: 1. To assess heart rate variability and soluble adhesion molecules ICAM-1 (intercellular adhesion molecule-1) and VCAM-1 (vascular cells adhesion molecule-1) in patients with coronary artery disease and healthy control and to evaluate the usefulness of the markers of impaired autonomic function and endothelial activation as predictors of adverse prognosis in patients with acute coronary syndromes. 2. The impact of early initiation of low and moderate-dose rosuvastatin treatment on autonomic function and concentrations of soluble adhesion molecules during the first 12 weeks post ACS without ST segment elevation.
Methods

Study protocol
The study consisted of two phases. In the first phase two groups of patients with coronary artery disease (acute coronary syndromes without ST segment elevation and stable angina pectoris) and one control group of subjects were included for comparisons of soluble levels of adhesion molecules and heart rate variability. Between December 2001 and July 2002, a total number of 136 patients were involved in the study. Patients were divided into three groups according to the clinical diagnosis. The first group consisted of 75 patients with non-ST segment elevation ACS (unstable angina and non ST elevation myocardial infarction). Unstable angina (UA) patients (n=57) had ischemic chest pain at rest within the preceding 48 hours that had developed in the absence of an extracardiac precipitating cause with either ST segment depression of >0.1 mV or T wave inversion in two or more contiguous leads on the presenting 12 lead ECG. Patients with non ST elevation myocardial infarction (n=18) had similar diagnostic criteria along with elevation of serum creatine kinase, without the evolution of pathological q waves. The second group consisted of 36 patients with stable angina pectoris (SAP) who had typical exertional angina pectoris and positive stress test. Patients with angina at rest were excluded from this group. The control group comprised of 25 healthy volunteers in the same age of distribution, without angina symptoms and with normal physical examination and stress test. Subjects with acute or chronic inflammatory diseases, malignancies, renal insufficiency, and severe liver disease, on immunosuppressive and antibiotic treatment were excluded from the study. Also excluded were patients with acute ST elevation myocardial infarction, diabetes mellitus, and history of myocardial infarction, surgical intervention or major trauma within the preceding month. A six months follow-up of patients with ACS was assessed by regular clinical examination for every month. Primary outcome was defined as cardiac death, non-fatal myocardial infarction or recurrent hospital admission for severe unstable angina. After the 6-month period of observation the study population was divided into two groups -with favorable course of the disease and with occurrence of adverse coronary events. In the second phase other 30 patients with ACS were allocated into two groups, and received rosuvastatin 10 mg/day (n =16, mean age 57.25±2.2 years) or rosuvastatin 20 mg/day (n =14, mean age 57.64±3.1 years). The randomization was carried out by the adaptive dynamic random allocation method irrespective of serum lipids levels. A followup assessment of both HRV on ambulatory ECG monitoring and adhesion molecules levels was performed during study period of 12 weeks. All patients were under treatment with the same medications during the acute phase of the episode (aspirin, nitrates, beta blockers, ACE inhibitors), according to the guidelines.
Biochemical analysis
Blood samples from ACS patients were collected after admission in the ICU prior to the onset of the antiischemic and anticoagulant therapy with a closed Vacutainer system (Beckton Dickinson, NJ, USA) and after 12 weeks for patients included into the second phase of the study. In SAP group and in controls, blood samples were collected at the time of clinical admission. The serum was separated after centrifugation at 3000 g for 10 min until 1 hour after taking the samples and sent in Department of Clinical Laboratory, Saint Anne University hospital for analyses of creatine kinase, cholesterol and triglycerides levels as a part of routine patient management. Two aliquots of the serum were centrally stored at -80°C and sent in batches to the Department of Clinical Laboratory and Clinical Immunology, Medical university, Sofia (for analyses of cTnT and hsCRP) and to the Section of Molecular Immunology, Bulgarian Academy of Sciences, Sofia (for analyses of VCAM-1 and ICAM-1). Determination of cTnT, hsCRP and soluble adhesion molecules levels was performed at the end of the study period, blinded to patients' histories and allocated treatment. Quantitative detection of serum concentrations of sVCAM-1 and sICAM-1 was performed using an enzyme linked immunosorbent assay (ELISA) technique employing a commercially available assay kit (BenderMed Sysytems, Vienna, Austria). The intra-and interassay coefficients of variation were 3.1%, 5.2% for VCAM-1 and 4.1%, 7.6% for ICAM-1 respectively. The levels of cardiac troponin T (cTnT) were determined by a third generation troponin STAT electrochemiluminescent immunoassay on the ELECSYS 1010 (Roche Diagnostics, Basel, Switzerland) with the detection limit at 0.01 ng/ml and a total coefficient of variation (CV) of 6% at 5.07 ng/ml and 9.3% CV at 0.10 ng/ml. High-sensitivity Creactive protein was measured with a CardioPhase hsCRP immunonephelometric assay (Dade Behring Inc) on BN systems. The detection limit was 0.175 mg/l with a total CV of 7.6% at 0.41 mg/l. 
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Results
Markers of endothelial activation and impaired autonomic function in patients with
acute coronary syndromes -Potential prognostic implication 3.1.1 Characteristics of the study population Table 1 demonstrates clinical characteristics and biochemical data of all study groups. There were no significant differences among study groups regarding age, gender, family history and smoking status. The patients with coronary artery disease (acute coronary syndromes and stable angina) had significantly higher rates of hypertension and dyslipidaemia compared with healthy control group. The presence of coronary risk factors was equal among groups with acute coronary syndromes and stable angina pectoris. Eight of the patients in the control group (32%) were on antihypertensive medications. The corresponding number of patients on antihypertensive medications in ACS group was 48 (64%) and 21 (61%) in stable angina pectoris group. All soluble ICAM-1, VCAM-1 and hsCRP significantly discriminated between patients with ACS and SAP (p=0.014, 0.05 and 0.025 respectively) and control subjects (p<0.001, 0.05 and 0.048). Soluble ICAM-1 and hsCRP were also elevated in patients with SAP compared with control group whereas no difference in sVCAM-1 was found (p<0.001, 0.05 and 0.4). In opposite, all the parameters of the frequency domain HRV tented to be lower in patients with ACS compared with stable angina and control group. In healthy subjects VLF, LF and HF were elevated, but LF/HF ratio was lower in comparison with stable angina patients (p=0.006). Table 1 . Baseline characteristics of study population
Baseline characteristics of patients with ACS according to clinical outcome
During the six month follow-up of the patients with acute coronary syndromes three patients (4%) died suddenly, seventeen (22.7%) suffered a non-fatal myocardial infarction and eight (10.7%) had recurrent UA, for a major adverse cardiovascular event rate of 37.3%. The majority of ischemic events occurred within 30 days of the initial episode of non ST elevation acute coronary syndrome -16 (57.14%). Simultaneously, the risk of development of non-fatal AMI and rehospitalization for recurrent UA remained significant even during a longer period of observation as 12 (42,8%) of the subsequent complications occurred during the period between the 30th day and the 6th month. On Table 2 the demographic, clinical and laboratory data of the patients with major cardiovascular events were compared with those of the patients with favorable outcome. Both groups do not differ concerning the classical risk factors for the development of ischemic heart disease such as age, gender, history of arterial hypertension, tobacco smoking, obesity, familial history and indices of lipid profile. The patients have received identical drug therapy including heparin (97,3%), acetysal (90,7%), β-blocker (73,3%), nitrate (100%), ACE-inhibitor (48%) and diuretics (17,3%). The patients with subsequent complications presented more often with Killip class over 1 (28,6% versus 8,5%, p=0,047) and with a significantly lower left ventricular ejection fraction on the echocardiographic examination performed between day 3 and day 7 of the hospitalization (54,6% versus 60,4%, p=0,003). Concentrations of sVCAM-1 (1488,75 ng/ml versus 1071,45 ng/ml, p<0,001), sICAM-1 (516,7 vs 433,3 ng/ml, p=0,010), hsCRP (32.6 vs 5.31 mg/l, p=0.001) and cTnT (0,72 vs 0,115 ng/ml, p<0,001) at presentation were significantly raised in patients who went on to have ischemic events during the six months of follow-up. None of the parameters of HRV was significantly associated with the occurrence of the composite endpoint. Although the prognostic information of frequency domain HRV indices was low, we found out that 2 variables -reduced LF (27±1.7 vs 65.1±10 ms, p=0.05) and LF/HF ratio (0.5±0.2 vs 2.94±0.4, p=0.004) were significantly predictive of death, but no for other endpoints (Fig 1) No event n (%) Table 3 presents the associations between soluble adhesion molecules, high sensitivity Creactive protein and troponin T in patients with ACS. There is a moderately strong positive correlation between the levels of sICAM-1 and sVCAM-1 (Spearman's r=0,205, p=0,028). Levels of sICAM-1 showed a strong correlation with hsCRP. The correlation between sVCAM-1 and hsCRP was r=0.144, p=0.11. In acute coronary syndromes levels of the myocardial necrosis marker troponin T correlated highly significant with hsCRP (r=0.451, p=0.001), but showed no interdependence with sVCAM-1 (r=0.106, p=0.383) and sICAM-1 (r=0.129, p=0.286). Table 4 . Associations between HRV and soluble adhesion molecules, high sensitivity Creactive protein and troponin T
Soluble adhesion molecules and cardiovascular events
The ROC analysis was performed to provide an index for assessment of the accuracy of the variable investigated to discriminate between subjects with cardiovascular complications and those without it. The data obtained from it demonstrate threshold concentrations of 0,01 ng/ml for cTnT (area under the curve 0,803, p=0,001), 4 mg/l for hsCRP (AUC 0,859, p=0,001), 1153,4 ng/mL for sVCAM-1 (AUC 0,786, p=0,001) and 438 ng/mL for sICAM-1 (AUC 0,671, p=0,017) Fig 2. 
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A total of 37 patients (49.3%) had a concentration of sVCAM-1>1153.4 ng/ml and the ischemic event rate for these patients was 78.6%. The remaining 38 patients had sVCAM-1 concentrations <1153.4 ng/ml and the ischemic event rate in this group was 21.4% (Pearson x2= 15,28, p<0,001). As Figure 3 A shows the difference was mainly driven by an increased rate of non-fatal myocardial infarction and rehospitalsation for unstable angina in the group of patients with high sVCAM-1 levels. Although the incidence rate of the ischemic complications in the patients with sICAM-1>438 ng/ ml was 66,7% while in the patients with subthreshold concentration of this parameter it was only 33,3%, a statistically reliable difference was lacking (Pearson x2=2,71,p<0,140, Figure 3 B ). The sensitivity of a concentration of sVCAM-1>1153.4 ng/ml for predicting future ischemic events was 79%, with a specificity of 68%. The negative predictive value was 84%. The sensitivity of sICAM-1>438 ng/ml for predicting a future ischemic events was 66%, with a specificity of 53% and negative predicting value of 72%. 
Multivariate risk stratification
In a multivariate analysis that included baseline characteristics and biochemical markers (Table 5) sVCAM-1 remained an independent and powerful predictor of increased cardiac risk at 6 months follow-up. The odds ratio associated with the highest value of sVCAM-1 was 4.62 (95% CI 1.8-11.4, p=0.0009) without adjustment and remained significantly elevated after adjustment for Killip class and left ventricular ejection fraction in model 2 (RR 4.63, 1.8-11.7, p=0.0012), troponin T in model 3 (RR 3.93, 1,5-10, p=0.04) and C-reactive protein in model 4 (RR 2.22, 0.8-5.7, p=0.05) Figure 4 . CRP>4 mg/l cTnT>0.01 ng/ml Killip>1&EF<50% VCAM>1153.4 ng/ml In order to assess the exact role of the increased soluble adhesion molecules levels we analyzed the combined predictive value of these two molecules with that of the already established prognostic indicators among ACS patients -troponin T and hs C-reactive protein. Division of the patients into 4 groups based on their sCAM and cTnT levels revealed that sVCAM-1 is an independent prognostic indicator of major adverse coronary events during the six months follow-up. In the patients admitted to the ICU without any detectable levels of the marker of cardiomyocyte necrosis (n=39) the incidence rate of the ischemic events was 1,3% when combined with low levels of sVCAM-1 and 6,7% when combined with sVCAM-1> 1153,4 ng/ml (Pearson χ2=6,03, p<0,024, Figure 5 A) . Simultaneously, the high sICAM-1 levels do not improve the prognostic value of troponin T as there was no statistically significant difference in the incidence rate of the complications in the patients with a negative cTnT test in dependence on the low or high sICAM-1 levels (the incidence of the complications was 2,9% and 5,7%, respectively) (Figure 5 B) . Furthermore, the predictive value of VCAM-1 was independent of systemic inflammation as evidenced by C-reactive protein. High VCAM-1 serum levels indicated increased cardiac risk both in patients with high CRP serum levels (25.3%% vs 6.7%, p=0.024) and in those with low CRP serum levels (4% vs 1.3%, p=0.05), Figure 6 . 
Markers of endothelial activation and impaired autonomic function in patients with acute coronary syndromes -Potential therapeutic implication 3.2.1 Characteristics of the study population
During the second phase of the study 30 patients with ACS were allocated into two groups, and received rosuvastatin 10 mg/day (n =16, mean age 57.25±2.2 years) or rosuvastatin 20 mg/day (n =14, mean age 57.64±3.1 years) for 12 weeks. Baseline characteristics for each group are presented in Table 6 , showing no significant differences between the two treatment groups. Furthermore, no significant differences in lipids, HRV and markers of endothelial activation were observed at baseline. After 3 months, patients in the 20 mg rosuvastatin group demonstrated a significant decrease in serum levels of sICAM-1 and sVCAM-1 (Table 8 , Figure 7 and 8). Also in the 10 mg-rosuvastin group, there was a significant decrease of sICAM-1 (Figure 9 ). However, no changes in sVCAM-1 levels were observed in this group of patients (Table 8, Figure 10 ). There were no significant differences in changes between the two treatment groups for either soluble adhesion molecules levels, but for sICAM-1 we found out a trend towards lower concentrations in the moderately treated group (p=0.07). No correlations were found between changes in LDL-cholesterol over 12 weeks and changes in s- p=0.29), p=0.31) and HRV during the same period. The Spearman's correlation coefficients between hsCRP and sICAM-1 (r=0.059, p=0,7) and sVCAM-1 (r=0.15, p=0,4) are low and not statistically significant. In ACS group, a significant inverse correlation was observed between markers of endothelial activation and HRV variables, with the strongest association being found for sVCAM-1 and HF amplitude (r =−0.506, p= 0.004) and LF amplitude (r=-0,4, p=0.02). In addition, sympathovagal balance was shifted to greater vagal predominance with 20 mg rosuvastatin (increase of HF and decrease of low frequency/ high frequency ratio) when compared to lower dose of 10 mg, p=0.05, 
Discussion
The measurement of ICAM-1 and VCAM-1 in prospective studies is based on the presence of an inflammatory process in the artery wall which increases the expression of adhesion molecules and on the hypothesis that the serum levels of these molecules reflect their expression by the endothelial cells. In this study we had measured the two main representatives of the immunoglobulin gene superfamily of CAM and found significantly higher levels of both sVCAM-1 and sICAM-1 in patients with ACS as compared with those with SAP and healthy controls. Our finding that soluble adhesion molecules and especially sVCAM-1 are strongly and independently predictive for future CV events in patient with ACS extends previous observations describing the predictive value of inflammatory markers on future cardiac events. However, whereas the causative role of C-reactive protein in promoting the inflammatory component in development of plaque rupture remains controversial, our data implicate a direct mediator of an inflammatory vessel wall process. Several arguments support the hypothesis that sCAM may be more useful than other markers of inflammation in predicting clinical outcome: First, all sICAM-1 and sVCAM-1 measured in our study are elevated in patients at risk for future cardiovascular events. Second, sCAM levels did not correlate with cTnT, a specific marker of cardiomyocyte necrosis and the most established prognostic marker in patients with ACS. The risk related to the high sVCAM-1 concentrations is independent of the cTnT that is evident from the increasing rate of complications in the groups with negative and positive cTnT in dependence on sVCAM-1 levels. These data suggest that VCAM-1 release actually precedes myocardial injury and that VCAM-1 elevation identifies patients with unstable atherosclerotic plaque formation even before complete microvascular obstruction. In contrast, we do not find any relationship between sICAM-1 and the risk of subsequent events in the course of the follow-up and we do not read any enhanced incidence rate of vascular events in the patients without laboratory evidence of a cardiomyocyte necrosis in dependence on the levels of this parameter. Third, sVCAM-1 levels did not correlate with Creactive protein, a systemic marker of inflammation. Because hsCRP correlated with cTnT levels elevated CRP serum levels most likely reflect both a robust vascular inflammatory response and myocardial injury. The measurement of sVCAM-1 added to the predictive value of hsCRP in determining the risk of future cardiovascular events. Even patients with low hsCRP levels were found to be at significantly higher risk with elevated sVCAM-1 levels which suggest that endothelial activation and proteolytic cleavage of sCAM is a primary event and is followed by release of other systemic mediators and acute phase proteins such as C-reactive protein.
Prospective data of soluble adhesion molecules are sparse. The results of our study correspond to the data published in the literature about the relationship between sCAM and the risk of cardiovascular events and they find their explanation in some differences between the two adhesion molecules studied. In the large prospective trials ARIC and PHS of healthy individuals, sICAM-1, but not sVCAM-1 appears consistently related to incident CAD [de Lemos et al., 2000; Hwang et al., 1997; Ridker et al., 1998 ]. ICAM-1 expression is not only endothelial and ICAM-1 is constitutively expressed by a variety of cell types including cells of the hematopoietic lineage and fibroblasts. sICAM-1 correlates with acute phase reactants like CRP and provides similar predictive information to CRP in settings of primary prevention [Blankenberg et al., 2003; Mulvihill et al., 2002; Ridker et al., 1998; . sICAM-1 therefore appears as a general marker of a proinflammatory status with little prognostic information in patients with ACS after controlling the data for troponin T and Creactive protein (Figure 5 and 6 ). By contrast, VCAM-1 is not expressed in baseline condition, but is rapidly induced by pro-atherosclerotic conditions in animal models and humans [Cybulsky&Gimbronejr, 1991; O'Brien et al., 1993] . It seems that sVCAM-1 represents an appropriate marker of plaque burden or activity of a potential clinical importance as a prognostic indicator under the conditions of secondary prevention rather than in healthy individuals without endothelial dysfunction [Blankenberg et al., 2003; Mulvihill et al., 2002] . A similar hypothesis is supported by the data proving the independent predictive value of sVCAM-1 in the patients with angiographically proven coronary artery disease [Blankenberg et al., 2001] , with diabetes mellitus [Jager et al., 2000] and with ACS [Mulvihill et al., 2001 [Mulvihill et al., , 2002 as well as its absence in healthy individuals [de Lemos et al., 2000] . The relationship between depressed HRV and mortality is difficult to ascertain as the exact physiological mechanisms responsible for the various HRV components are still incompletely known [Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, 1996; Tsuji et al., 1996] . Decreased values of HRV variables, including LF, may reflect reduced vagal tone or predominant sympathetic influence to the heart. The presence of frequent or complex non-sustained VA in the context of sympathovagal imbalance can increase the susceptibility to fatal VA, in particular during myocardial ischaemia [Kent et al., 1973; Lanza et al., 1998 Schwartz et al.,1988] . On the other hand, VA and depressed HRV are unlikely to be associated with the triggers of acute MI, as they were not predictive of non-fatal MI in hospital or at six-month follow up. Recent experimental findings have suggested that the nervous autonomic system can significantly modulate inflammatory reactions [Wang et al., 2003 ]. In particular, vagal stimulation has been shown to decrease inflammatory reactions in animals by inhibiting tissue macrophage activation, an effect mediated by stimulation of the alpha-7 subunit of the macrophage nicotine receptor by the vagal neurotransmitter acetylcholine, whereas adrenergic activity has been reported to favor sympathectomy and towards inflammatory reactions. Conversely, several products of inflammation have been shown to have potential influence on nervous autonomic activity by central and/or peripheral mechanisms Tracey,2002] . The low and no significant correlations between markers of endothelial activation and HRV in the present study emphasize that neural influence unlikely explained the observed predictive value of soluble adhesion molecules in patients with ACS. ACS is a diffuse process involving the entire coronary vasculature [Buffon et al., 2002] . Although mechanical revascularization by percutaneous coronary intervention may address the culprit lesion, recurrent events may reflect disease progression or instability elsewhere in the vascular tree. Stabilization of vulnerable plaques or modulation of the so-called vulnerable patient is becoming recognized as an important target for systemic therapy [Libby&Aikawa 2003; Naghavi et al., 2003a Naghavi et al., , 2003b . The rapid pleiotropic effects of statins on inflammation, endothelial function, and coagulation are likely to be particularly beneficial in patients with ACS in whom these systems are deranged. Inhibition of HMG CoA reductase by statins inhibits cholesterol synthesis and isoprenoid production. This results in reduced prenylation of small G-proteins such as Rho and, in turn, NF-κB activation. By inhibiting HMG CoA reductase, statins can prevent the biosynthesis of isoprenoids such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate. Inhibition of Rho geranylgeranylation by statins can reduce leukocyte adhesion and fibronolytic activity [Rasmussen et al., 2003; Yoshida et al.,2001] . A recent report suggests additional mechanism which is independent of mevalonate production -statins bind to a novel allosteric site within the ß2-integrin leukocyte function-associated antigen-1 (LFA-1), preventing binding to the counterreceptor on the endothelial surface (ICAM-1) [WeitzSchmidt et al., 2001 ]. In addition, statins can induce endothelial nitric oxide synthase (eNOS) accumulation in endothelial cells, an effect dependent on the inhibition of Rho geranylgeranylation, reduce the activation of monocyte/macrophage system, the cytotoxicity of T-lymphocytes and the balance between Th-1/Th-2 subclass. Hence, statins modify the immune response in ACS via reductions in inflammatory cell number, adhesion, and activation at potentially vulnerable sites along the wall [Liao, 2002; Libby&Aikawa 2003 ]. I n a n i m a l m o d e l s H M G -C o A r e d u c t a s e i n h i b i t o r s h a v e b e e n s h o w n t o r e d u c e r e n a l sympathetic nerve traffic [Pliquett et al., 2003] . To date, the underlying mechanism by which statins reduce sympathetic outflow has not been elucidated. An effect on central nitric oxide (NO) and reactive oxygen species (ROS) formation, as well as regulation of the AT1-receptor expression, have been proposed as possible explanations [Gao et al., 2005; Gomes et al., 2010; Hirooka et al., 2010; Patel et al., 2001] . Contradictory results have been published about the effect of statins on sICAM-1 and sVCAM-1 plasma/serum concentrations in patients with various clinical manifestation of ischemic heart disease. In a number of small population studies, different authors have noted that treatment with statins diminished sICAM-1 concentrations in subjects with hypercholesterolemia or CHD [Ascer et al., 2004; Patti et al., 2006] . However, Wiklund et al., 2002 observed a small and inconsistent effect of simvastatin and atorvastatin treatment in hypercholesterolemic patients. Furthermore, Jilma et al., 2003 , demonstrated that atorvastatin, simvastatin, or pravastatin did not modify sICAM-1 concentrations after 3 months of treatment in subjects with moderate hypercholesterolemia. Blanco-Colio et al. 2007 , investigate the effect of 10-, 20-, 40-and 80 mg Atorvastatin on sICAM-1 and MCP-1 levels in 2117 patients with CHD in Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration Trial and didn't found statistically significant differences between the various doses used. Although atorvastatin had a weak effect on sICAM-1 concentrations in the whole population [-2.2 % change (95% confidence interval -3.8 to -0.6%); P =.006], in the highest quartile all doses of atorvastatin diminished sICAM-1 plasma levels by more than 10% in subjects at high cardiovascular risk, indicating that atorvastatin has a greater effect in subjects with higher systemic inflammation. In the large PROVE-IT TIMI 22 study Ray et al. 2006 didn't found significant difference between intensive (80 mg Atorvastatin) and standart (40 mg Pravastatin) regiment on sICAM-1 levels at 30 days. However, when considered the relation among statin therapy, sICAM-1 levels, and clinical outcomes, the authors found that the risk of adverse events for patients with a sICAM-1 level >231 ng/ml appeared more marked among those allocated to standard dose statin therapy (each odds ratio >2.1). The observed pattern raises the hypothesis that the risk associated with sICAM-1 may be attenuated by treatment with intensive statin therapy (each odds ratio <1.5).
In this study we have analyzed the effect of two rosuvastatin regimens on sICAM-1 and sVCAM-1 concentration in patients with high risk ACS defined by the levels of soluble www.intechopen.com
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with Acute Coronary Syndromes -Potential Prognostic and Therapeutic Implication 199 adhesion molecules. We observed that the treatment with rosuvastatin diminish both markers of endothelial activation during 12 week follow-up. We found out a trend towards lower concentrations of sICAM-1 in patients randomized to 20 mg Rosuvastatin, in addition to the previously observed significant lowering of low-density lipoprotein and C-reactive protein.
There was no correlation between sCAMs and low-density lipoprotein and hsCRP at month 3 and the effect of rosuvastatin on soluble CAMs did not appear to be explained by changes in lipids or inflammatory markers. However, standart statin therapy did not significantly alter sVCAM-1 levels at 3 months. The present observations with sVCAM-1 are analogous to the observations with aspirin and clopidogrel in which each drug decreases the risk of adverse clinical events in subjects with high CRP levels but do not decrease CRP significantly [Chew et al., 2001; Kennon et al., 2001; Ridker et al., 1997] . A potential mechanistic explanation for our clinical observations is, that among subjects with increased endothelial activation, a more potent statin regimen could bind to lymphocyte function-associated antigen-1 on inflammatory cells to a greater extent, thus interfering with downstream effects of increased endothelial activation rather than decreasing endothelial activation itself. This hypothesis raises the possibility that novel therapeutic strategies that target inhibition of adhesion molecules may be of benefit in ACS, as has been demonstrated in animal models and in patients with inflammatory bowel disease [Gill et al., 2005; Van Assche et al., 2005 ]. An interesting finding was the observed beneficial effect of more intense statin regiment on some parameters of autonomic function. During the study period we found out a significant increase of high frequency component with represents the parasympathetic contribution to the spectrum, whereas low frequency remained unchanged. As a result, the LF/HF ratio, measure of autonomic balance was reduced significantly in patients received 20 mg Rosuvastatin. The results of the correlation analysis clearly suggest that some of the beneficial effects of more potent statin dose may be driven by the effect on endothelial and autonomic function Patti et al., 2006] . Supports for this hypothesis are the results of the meta-analysis of Patti et al, who found that high-dose statin pretreatment before percutaneous coronary intervention leads to a significant reduction in periprocedural myocardial infarction and 30-day adverse events. It is noteworthy that the effect is most pronounced, but is not limited in patients with elevated markers of inflammatory activity [Patti et al., 2011] . Our findings must be confirmed by larger studies. It may contribute to the achievement of specific treatment goals for each patient with proper drug selection and dose titration in high risk patients such as those with elevated markers of endothelial activation and depressed HRV.
Conclusions
In patients with ACS, soluble adhesion molecules are independent predictors of subsequent MACE and reduced HRV of medium-term mortality, suggesting that markers of endothelial activation and impaired autonomic function should be taken into account in the risk stratification of these patients. Our findings support the hypothesis that statins decrease endothelial injury and activation in patients with acute coronary syndromes. In addition we found that more aggressive regiment with early initiation of 20 mg Rosuvastatin significantly decreases sICAM-1 levels
